Verition Fund Management
RVNC

Verition Fund Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Verition Fund Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-54,805
Closed -$284K – 3586
2024
Q3 		$284K Buy
54,805
+10,501
+24% +$52.2K ﹤0.01% 2678
2024
Q2 		$114K Buy
44,304
+22,340
+102% +$76.3K ﹤0.01% 2715
2024
Q1 		$108K Buy
+21,964
New +$130K ﹤0.01% 2577
2023
Q2 		– Sell
-7,373
Closed -$237K – 2617
2023
Q1 		$237K Buy
+7,373
New +$230K ﹤0.01% 1666
2018
Q2 		– Sell
-7,567
Closed -$233K – 1377
2018
Q1 		$233K Buy
+7,567
New +$243K 0.02% 936

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Verition Fund Management's RVNC Position: Q4 2024 in Review

Verition Fund Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 54,805 shares — an estimated $284K sold.

Verition Fund Management first reported a position in RVNC in Q1 2018 and held it in 5 quarters. The position peaked at $284K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Verition Fund Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Verition Fund Management sold 54,805 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $284K.
  • Verition Fund Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
  • Verition Fund Management's Revance Therapeutics, Inc. position peaked at $284K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Verition Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.